Johnson and Johnson delivers another excellent quarter
This article was originally published in Clinica
US healthcare conglomerate Johnson & Johnson has reported another strong quarter in the three months to September. Fuelled by the Palmaz-Schatz coronary stent, professional products sales rose 27% to $1,679 million in the third quarter, outperforming J&J's consumer product and pharmaceutical divisions. Kurt Kruger, an analyst at brokers Hambrecht & Quist, estimates the stent's sales will reach $450 million this year.